Login
$SANA
$1.89 +$0.01 (0.53%) After hours

Company Executives

Officer Age In this role 2025 pay Source
Steven D. Harr Also a director
President & CEO
Title from the Form 4 dated Mar 6, 2026
55 Not stated $2,903,010
Brian Piper
Executive Vice President, Chief Financial Officer
54 Since 2026
this year
Not reported
Dhavalkumar Patel
Executive Vice President, Chief Scientific Officer
64 Since 2024
2 years
Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
9
serving now
Average tenure
6.6 years
from year joined
CEO also chairs the board
No
Hans E. Bishop
Director Age On board Committees Other public boards 2025 pay Source
Hans E. Bishop
62 2018
8 years
Audit Committee
None stated $220,515
Steven D. Harr, M.D.
55 2018
8 years
None stated None stated Paid as CEO
Robert Nelsen
62 2018
8 years
None stated Hua Medicine $162,787
Alise S. Reicin, M.D.
65 2020
6 years
None stated Immatics N.V., Tectonic Therapeutic, Inc. $170,287
Joshua H. Bilenker, M.D.
54 2020
6 years
Nominating and Corporate Governance Committee · Chair
None stated $169,517
Richard Mulligan, Ph.D.
71 2018
8 years
None stated Bausch Health Companies Inc., International Flavors and Fragrances Inc. $162,787
Robert L. Rosiello
68 2025
1 year
Audit Committee Compensation and Talent Committee
Seres Therapeutics, Inc. $230,696
Michelle Seitz, CFA
60 2020
6 years
None stated MetLife, Inc., MSCI, Inc. $182,787
Patrick Y. Yang, Ph.D.
78 2018
8 years
None stated None stated $167,787

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

8 disclosed in the proxy filed Apr 24, 2026
Entities affiliated with FMR LLC
a holder of more than 5% of our capital stock as of the time of the August 2025 Offering
$7,999,998
August 2025

Purchased shares of our common stock from the underwriters in the August 2025 Offering

With the underwriters Open in proxy
Entities affiliated with ARCH Venture Partners
certain holders of more than 5% of our capital stock as of the time of the February 2024 Offering
$ 9,999,996
February 2024

Purchased shares of our common stock from the underwriters in the February 2024 Offering

With the underwriters Open in proxy
Entities affiliated with Baillie Gifford & Co.
certain holders of more than 5% of our capital stock as of the time of the February 2024 Offering
$ 4,950,000
February 2024

Purchased shares of our common stock from the underwriters in the February 2024 Offering

With the underwriters Open in proxy
Entity affiliated with Flagship Pioneering Funds
certain holders of more than 5% of our capital stock as of the time of the February 2024 Offering
$ 14,999,723
February 2024

Purchased pre-funded warrants from the underwriters in the February 2024 Offering

With the underwriters Open in proxy
Entities affiliated with FMR LLC
certain holders of more than 5% of our capital stock as of the time of the February 2024 Offering
$ 18,638,950
February 2024

Purchased shares of our common stock from the underwriters in the February 2024 Offering

With the underwriters Open in proxy
Entities affiliated with ARCH Venture Partners
owns, in the aggregate, more than 5% of our common stock
Amount not stated
February 2019

Party to the amended and restated investors' rights agreement granting registration rights

Brian Harr
Dr. Harr’s brother
Amount not stated
February 2019

Party to the amended and restated investors' rights agreement granting registration rights

Mr. Nelsen
a member of our Board; affiliated with ARCH Venture Partners
Amount not stated

Interest in Beam, the counterparty to the Beam License Option and License Agreement entered in October 2021

With Beam Therapeutics Inc. Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support